Home » Stocks » VTGN

VistaGen Therapeutics, Inc. (VTGN)

Stock Price: $2.13 USD -0.20 (-8.58%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $2.12 -0.01 (-0.47%) May 13, 7:31 PM
Market Cap 403.23M
Revenue (ttm) 647,600
Net Income (ttm) -16.35M
Shares Out 190.20M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.13
Previous Close $2.33
Change ($) -0.20
Change (%) -8.58%
Day's Open 2.32
Day's Range 2.08 - 2.38
Day's Volume 1,921,603
52-Week Range 0.35 - 3.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?

Other stocks mentioned: ATOS, CTXR
2 weeks ago - PennyStocks

Penny stock watchlists? Why they're not as complicated as they seem The post Penny Stocks Watchlists and How to Make One appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other stocks mentioned: BIOL, DPW
2 weeks ago - PennyStocks

The COVID-19 pandemic has exacerbated mental health issues and is triggering new conditions for people already suffering from mental illnesses and substance abuse.  Social anxiety disorder (SAD) is one ...

2 weeks ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the po...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicine...

1 month ago - GlobeNewsWire

PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders PH10 may have stand-alone potential to displace current oral antidepr...

2 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CVE, INFI, ASC, CHRA
2 months ago - 24/7 Wall Street

An analyst is very bullish about the biotech.

2 months ago - The Motley Fool

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

3 months ago - Zacks Investment Research

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)

3 months ago - GlobeNewsWire

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, prima...

3 months ago - Seeking Alpha

Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review Dr. Louis...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines...

4 months ago - GlobeNewsWire

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.

Other stocks mentioned: BCRX, TDOC
4 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potentia...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potentia...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

9 months ago - PRNewsWire

SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 31, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression an...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression,...

11 months ago - PRNewsWire

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

1 year ago - Zacks Investment Research

VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.

1 year ago - Zacks Investment Research

Vistagen Therapeutics Inc (NASDAQ: VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate.

2 years ago - Benzinga

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment diso... [Read more...]

Industry
Biotechnology
Founded
1998
Stock Exchange
NASDAQ
Ticker Symbol
VTGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is 5.67, which is an increase of 166.20% from the latest price.

Price Target
$5.67
(166.20% upside)
Analyst Consensus: Strong Buy